Improving antidepressant adherence.

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Frequently, patients suffering from depressive disorders discontinue antidepressant treatment due to the unpleasant side effects of these medications, particularly in the first month of therapy. Good tolerability (particularly in the early stages of treatment), patient education, and the quality of the relationship between physicians and patients are all common determining factors of patient adherence. Controlled-release antidepressant agents have the potential to improve tolerability early in the course of therapy, one of the most likely periods of dropout from treatment. Side effects for controlled-release formulations are often more favorable because controlled-release formulations exhibit lower peak plasma drug concentrations when compared with immediate-release formulations. Venlafaxine extended-release (XR), bupropion sustained-release (SR), and paroxetine controlled-release (CR) are 3 commonly utilized controlled-release antidepressants that have demonstrated improvement over their immediate-release predecessors in reducing certain adverse effects.

Original languageEnglish
Pages (from-to)25-30
Number of pages6
JournalThe Journal of clinical psychiatry
Volume64 Suppl 18
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Antidepressive Agents
Therapeutics
Bupropion
Physician-Patient Relations
Paroxetine
Patient Education
Patient Compliance
Depressive Disorder
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Improving antidepressant adherence. / Nemeroff, Charles.

In: The Journal of clinical psychiatry, Vol. 64 Suppl 18, 01.12.2003, p. 25-30.

Research output: Contribution to journalArticle

@article{2b7f8bdce3cb48fabc9f1b73010f06a1,
title = "Improving antidepressant adherence.",
abstract = "Frequently, patients suffering from depressive disorders discontinue antidepressant treatment due to the unpleasant side effects of these medications, particularly in the first month of therapy. Good tolerability (particularly in the early stages of treatment), patient education, and the quality of the relationship between physicians and patients are all common determining factors of patient adherence. Controlled-release antidepressant agents have the potential to improve tolerability early in the course of therapy, one of the most likely periods of dropout from treatment. Side effects for controlled-release formulations are often more favorable because controlled-release formulations exhibit lower peak plasma drug concentrations when compared with immediate-release formulations. Venlafaxine extended-release (XR), bupropion sustained-release (SR), and paroxetine controlled-release (CR) are 3 commonly utilized controlled-release antidepressants that have demonstrated improvement over their immediate-release predecessors in reducing certain adverse effects.",
author = "Charles Nemeroff",
year = "2003",
month = "12",
day = "1",
language = "English",
volume = "64 Suppl 18",
pages = "25--30",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",

}

TY - JOUR

T1 - Improving antidepressant adherence.

AU - Nemeroff, Charles

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Frequently, patients suffering from depressive disorders discontinue antidepressant treatment due to the unpleasant side effects of these medications, particularly in the first month of therapy. Good tolerability (particularly in the early stages of treatment), patient education, and the quality of the relationship between physicians and patients are all common determining factors of patient adherence. Controlled-release antidepressant agents have the potential to improve tolerability early in the course of therapy, one of the most likely periods of dropout from treatment. Side effects for controlled-release formulations are often more favorable because controlled-release formulations exhibit lower peak plasma drug concentrations when compared with immediate-release formulations. Venlafaxine extended-release (XR), bupropion sustained-release (SR), and paroxetine controlled-release (CR) are 3 commonly utilized controlled-release antidepressants that have demonstrated improvement over their immediate-release predecessors in reducing certain adverse effects.

AB - Frequently, patients suffering from depressive disorders discontinue antidepressant treatment due to the unpleasant side effects of these medications, particularly in the first month of therapy. Good tolerability (particularly in the early stages of treatment), patient education, and the quality of the relationship between physicians and patients are all common determining factors of patient adherence. Controlled-release antidepressant agents have the potential to improve tolerability early in the course of therapy, one of the most likely periods of dropout from treatment. Side effects for controlled-release formulations are often more favorable because controlled-release formulations exhibit lower peak plasma drug concentrations when compared with immediate-release formulations. Venlafaxine extended-release (XR), bupropion sustained-release (SR), and paroxetine controlled-release (CR) are 3 commonly utilized controlled-release antidepressants that have demonstrated improvement over their immediate-release predecessors in reducing certain adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=1542545160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542545160&partnerID=8YFLogxK

M3 - Article

C2 - 14700452

AN - SCOPUS:1542545160

VL - 64 Suppl 18

SP - 25

EP - 30

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

ER -